Resources &
Events
Paradigm conducts research and development days, investor roadshows, investor days, virtual conferences and webinars and clinical updates. To stay up to date with everything happening at Paradigm, join our mailing list.
Next R&D Event
| Event | OARSI 2023 World Congress on Osteoarthritis |
| Location | Denver, CO |
| Date | March 16-20, 2023 |
Last updated 27/02/23 5:00pm
Next Investor Event
| Event | NWR Virtual Healthcare Conference |
| Location | Virtual |
| Date | March 21-22, 2023 |
Last updated 21/03/23 11:25am
Upcoming Events
Shifts in Thinking
Read how the Paradigm team is approaching innovation from completely different approach below. For all published articles please click here
WorldSymposium Poster
Safety and tolerability of PPS in MPS VI
Author: Roberto Giugliani et al.
February 22, 2022
ICIEM Poster
Safety and tolerability of PPS in MPS I
Author: Drago Bratkovic et al.
November 22, 2021
Development Plan
Potential of injectable PPS for knee OA
Author: Mukesh Ahuja MBBS, MS
May 22, 2022
Previous
Next
Peer-Reviewed Publications
Phase 2 study evaluating PPS efficacy and safety in MPS VI
Source: Giugliani R, et al
February 24, 2023
MPS VI: defining and measuring functional impacts in pediatric patients
Source: Leiro B, et al
December 2, 2021
Double-blind placebo-controlled phase 2 study to evaluate the safety & tolerability of PPS in subjects with MPS VI
Source: Giugliani, R. et. al.
February 10, 2022
An open-label single-centre pilot study to evaluate the safety and tolerability of PPS in subjects with MPS I
Source: Bratkovic, D. et al
November 23, 2021
Summary of peer reviewed publications supporting PPS mechanism of action for the treatment of osteoarthritis
Source: Paradigm Biopharma
August 5, 2021
Human osteocyte expression of Nerve Growth Factor: The effect of PPS & implications for pain associated with knee osteoarthritis
Source: Stapledon C. et al
September 26, 2019
Improved clinical outcome measures of knee pain & function with concurrent resolution of subchondral BME lesion and joint effusion in an osteoarthritic patient following PPS treatment: a case report
Source: Sampson, M. et al
September 12, 2017
Broad Th2 neutralization and anti-inflammatory action of PPS in experimental allergic rhinitis
Source: Sanden, C. et al
May 12, 2017
PPS: a novel glycosaminoglycan-like molecule for effective treatment of alphavirus-induced cartilage destruction & inflammatory Disease
Source: Herrero, L.J. et al
May 27, 2015
PPS decreases myocardial expression of the extracellular matrix enzyme ADAMTS4 & improves cardiac function in vivo in rats subjected to pressure overload by aortic banding
Source: Vistnes, M. et al
March 3, 2014
In the Media
Small Caps
Paradigm raises the stakes in osteoarthritis pain reduction
Focus: Osteoarthritis
August 15, 2018
AFR
Footballers Chris Judd, Leo Barry pile into Paradigm Raising
Focus: Capital Raise
December 13, 2019
NINE NEWS
Report on Andrew Walker and Paradigms’ EAP in the USA
Focus: Osteoarthritis
August 26, 2020
Previous
Next
Media Archive
2016
2017
2018
2019
2020
2021
2022
2016
Paradigm Biopharma
Press conference and performance update
Source: Paradigm Biopharma
October 4, 2016
Asthma
Lund University asthma presentation short with questions
Source: Prof. Jonas Erjefalt Lund University, Sweden
October 4, 2016
Ross River
Dr Lara Herrero, Griffith University, Australia
Source: Paradigm Biopharmaceuticals
October 4, 2016
Paradigm Biopharma
PPS brings new hope for Ross River Virus
Source: 7 News, Melbourne
September 8, 2016
Hay Fever
Potential breakthrough treatment for hay fever
Source: 7 News, Melbourne
September 8, 2016
Hay Fever
Nine news report on breakthrough in hay fever treatment
Source: 9 News, Melbourne
September 8, 2016
Hay Fever
Eyewitness report on new hope for hay fever sufferers
Source: 10 News, Melbourne
September 8, 2016
Ross River
Australian scientists discover life-changing therapy
Source: Guardian, Australia
September 8, 2016
Ross River
Announcement of Paradigm’s Ross River Virus breakthrough
Source: 10 News, Melbourne
September 8, 2016
Alphavirus Induced Arthralgia
Paradigm Biopharma announces PPS as a potential breakthrough in the treatment
Source: 7 News, Melbourne
September 7, 2016
Bone bruising
Elite athlete’s high hopes for bone bruising treatment
Source: 10 News, Melbourne
July 8, 2016
2017
Osteoarthritis
Paul Rennie in Interview with Dr Ross Walker
Source: Radio 2GB, Sydney
November 19, 2017
Osteoarthritis
Paul Rennie in Interview with Dr Ross Walker
Source: Radio 2GB, Sydney
November 19, 2017
Osteoarthritis
Promising results as Paradigm repurposes drug for osteoarthritis
Source: Sharon Smith, Stockhead
November 3, 2017
Osteoarthritis
High hopes for arthritis treatment
Source: The Australian, Australia
October 10, 2017
Osteoarthritis
Paradigm PPS treatment reduces pain
Source: Nine Finance, Online
October 10, 2017
Osteoarthritis
Innovation in drug development: Repurposing drug offers pharma growth
Source: Australian Financial Review, Online
October 6, 2017
Osteoarthritis
Paradigm receives ethics approval for osteoarthritis trial
Source: Lab Online, Online
September 21, 2017
Osteoarthritis
Radical drug trial revives Walker’s football career
Source: Riverine Herald, Echuca
September 15, 2017
Osteoarthritis
Could this be the end of osteoarthritis?
Source: NZ Herald, Online
September 12, 2017
Osteoarthritis
A Melbourne medical breakthrough could help millions of Australians who suffer from osteoarthritis
Source: News Adelaide, Adelaide
September 11, 2017
Osteoarthritis
Interview with Kaye O’Lachlan, arthritis patient
Source: 3AW Radio, Melbourne
September 11, 2017
2018
Osteoarthritis
Paul Rennie in interview with Tony Pilkington
Source: FIVEaa radio, Adelaide
December 20, 2018
Osteoarthritis
SA pharmaceutical firm Paradigm set to make billions from osteoarthritis drug
Source: The Advertiser, Adelaide
December 18, 2018
Paradigm Biopharma
Exploring Dr Boreham’s Crucible: Paradigm Biopharma
Source: Biotech Daily, Online
September 21, 2018
Osteoarthritis
Paradigm Biopharmaceuticals raises the stakes in osteoarthritis pain reduction
Source: Small Caps, Online
August 15, 2018
Osteoarthritis
Fast knee pain trial recruitment boosts Paradigm Biopharmaceuticals
Source: Small Caps, Online
August 6, 2018
Paradigm Biopharma
A report on the 5 biotechs that smashed the ASX200’s performance in 2018
Source: Emma Koehn, Stockhead
July 3, 2018
Osteoarthritis
Osteoarthritis trial recruitment ‘ahead of schedule’ plus Ross River developments
Source: SmallCaps, Online
May 17, 2018
Osteoarthritis
Ground breaking new treatment set to ease arthritis pain
Source: 9 News, Melbourne
March 3, 2018
Osteoarthritis
Greg Williams in interview with Gerard Healy and Dwayne Russell
Source: 3AW Radio, Melbourne
January 30, 2018
Osteoarthritis
Paradigm puts Diesel back in the swing
Source: The Australian, Australia
January 30, 2018
2019
Paradigm Biopharma
Small cap healthcare stocks surge to billion-dollar plays
Source: Australian Financial Review, Australia
September 30, 2019
Paradigm Biopharma
Footballers Chris Judd, Leo Barry pile into Paradigm capital raising
Source: Australian Financial Review, Australia
April 17, 2019
2020
2021
2022
